On March 24, 2021 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that it will report its fourth quarter and year-end 2020 financial results on Tuesday, March 30, 2021 (Press release, IGM Biosciences, MAR 24, 2021, https://igmbio.com/2021/03/24/igm-biosciences-to-announce-fourth-quarter-and-year-end-2020-financial-results-and-host-conference-call-and-webcast-on-march-30-2021/ [SID1234577063]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the earnings release, IGM’s management team will host a live conference call and webcast at 4:30 p.m. ET on Tuesday, March 30, 2021, to discuss the Company’s financial results and provide a corporate update.

A replay of the audio webcast will be available for 30 days on the Investors section of the Company’s website, www.igmbio.com.